Skip to content
DataLookout
Menu

NCT03728335

Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation

StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 18 versions: 17 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Trial status changed: Suspended → Active, Not Recruiting
    • Eligibility criteria expanded, about 31 words
    • Publications: details revised at 1 of 1 entry
    • Study description expanded, about 5 words
  2. Stopped Recruitment suspended Sponsor's reason: Accrual goal met
    • Start date: Jul 11, 2019 to Dec 23, 2019
    • Site details revised at 2 of 2 sites
    v17
  3. Minor Site details revised at 1 of 2 sitesv16
  4. Notable Trial status: Suspended to Recruiting
    • Site details revised at 2 of 2 sites
    v15
  5. Stopped Trial status: Recruiting to Suspended Sponsor's reason: Review
    • Site details revised at 2 of 2 sites
    v14
Show 11 earlier versionsHide 11 earlier versions
  1. Notable Phase: Phase 1 to Phase 2
    • Study description shortened, about 24 words
    • Site details revised at 1 of 2 sites
    • Study title shortened, about 8 words
    v12
  2. Notable Trial status: Active, Not Recruiting to Recruiting
    • Enrollment target: 15 to 35
    • Primary and study completion dates: Dec 15, 2024 to Jan 11, 2027
    • Site details revised at 2 of 2 sites
    v11
  3. Notable Primary and study completion dates: Dec 15, 2023 to Dec 15, 2024v10
  4. Notable Primary and study completion dates: Jun 15, 2023 to Dec 15, 2023v9
  5. Notable Primary and study completion dates: Dec 15, 2022 to Jun 15, 2023v8
  6. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 2 of 2 sites
    v7
  7. Notable Primary and study completion dates: Dec 15, 2020 to Dec 15, 2022
    • Site details revised at 1 of 2 sites
    v6
  8. Notable Eligibility criteria expanded, about 3 words
    • Interventions: Enasidenib (Drug), Enasidenib Mesylate (Drug) to Enasidenib Mesylate (Drug)
    • Secondary endpoints revised (5)
    • Study description expanded, about 10 words
    v5
  9. Notable Trial status: Not Yet Recruiting to Recruitingv4 Show 6 more changesShow less
    • Eligibility criteria shortened, about 2 words
    • Start date changed from estimate of Oct 15, 2019 to Jul 11, 2019
    • Interventions: Enasidenib (Drug) to Enasidenib (Drug), Enasidenib Mesylate (Drug)
    • Secondary endpoints revised (5)
    • Study description revised
    • Site details revised at 2 of 2 sites
  10. Notable Start date: Jun 15, 2019 to Oct 15, 2019v3
  11. Notable Start date: Dec 15, 2018 to Jun 15, 2019v2
  1. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incidence of adverse events (AEs)
Timeframe: Up to 30 days post treatment completion

Secondary (5)

Overall survival (OS)
Leukemia free survival (LFS)
Time to relapse
Non-relapse mortality (NRM)
Graft versus host disease (GvHD)-free relapse free survival (GRFS)

Arms and interventions

Treatment (enasidenib mesylate)Experimental

Patients receive enasidenib PO QD on days 1-28. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.

Drugs: Enasidenib Mesylate

Sites

2 sites in 1 country